UroGen Pharma (URGN) Set to Announce Quarterly Earnings on Wednesday

UroGen Pharma (NASDAQ:URGN) will post its quarterly earnings results before the market opens on Wednesday, November 6th. Analysts expect UroGen Pharma to post earnings of ($0.84) per share for the quarter. Investors that are interested in registering for the company’s conference call can do so using this link.

UroGen Pharma (NASDAQ:URGN) last released its quarterly earnings data on Tuesday, August 13th. The company reported ($0.91) EPS for the quarter, missing the consensus estimate of ($0.82) by ($0.09). The business had revenue of $21.85 million for the quarter, compared to analyst estimates of $23.69 million. On average, analysts expect UroGen Pharma to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

UroGen Pharma Stock Performance

NASDAQ:URGN traded down $0.11 on Tuesday, reaching $11.82. 204,812 shares of the company’s stock were exchanged, compared to its average volume of 501,501. The firm has a market cap of $277.23 million, a price-to-earnings ratio of -3.67 and a beta of 1.12. The company has a debt-to-equity ratio of 3.23, a current ratio of 8.15 and a quick ratio of 7.93. The stock has a fifty day simple moving average of $12.90 and a 200-day simple moving average of $14.22. UroGen Pharma has a 52 week low of $10.60 and a 52 week high of $20.70.

Wall Street Analysts Forecast Growth

Several research analysts have commented on the company. Guggenheim assumed coverage on UroGen Pharma in a research note on Thursday, August 22nd. They issued a “buy” rating and a $40.00 target price for the company. Oppenheimer reiterated an “outperform” rating and issued a $40.00 price objective on shares of UroGen Pharma in a report on Wednesday, October 16th. EF Hutton Acquisition Co. I upgraded shares of UroGen Pharma to a “strong-buy” rating in a research report on Monday, October 14th. Finally, HC Wainwright reissued a “buy” rating and set a $60.00 price objective on shares of UroGen Pharma in a research note on Tuesday, October 15th. Four equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Buy” and an average price target of $48.38.

About UroGen Pharma

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.